首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

基因治療市場規模、佔有率和成長分析（按基因類型、治療方法、載體類型、遞送方法、給藥途徑、應用和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1899716

基因治療市場規模、佔有率和成長分析（按基因類型、治療方法、載體類型、遞送方法、給藥途徑、應用和地區分類）－2026-2033年產業預測

Gene Therapy Market Size, Share, and Growth Analysis, By Gene Type (Antigen, Cytokine), By Therapy type, By Vector type, By Delivery Method, By Route of Administration, By Application, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 194 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球基因治療市場規模預計在 2024 年達到 90 億美元，從 2025 年的 109.3 億美元成長到 2033 年的 515.5 億美元，在預測期（2026-2033 年）內複合年成長率為 21.4%。

在全球基因治療市場持續強勁成長的推動下，科學的重大進步和遺傳性疾病發生率的上升趨勢日益顯著。血友病和囊腫纖維化等罕見疾病和慢性病的盛行率不斷攀升，推動了標靶基因治療方法的發展。 CRISPR-Cas9 和腺結合病毒載體等創新技術提高了基因轉移方法的精準性和安全性。關鍵治療方法的監管核准進一步刺激了投資和研究。然而，挑戰依然存在，包括治療費用高昂導致的可及性受限、病毒載體複雜的生產流程、免疫反應方面的安全隱患以及監管障礙，尤其是在新興市場。儘管有這些限制，但正在進行的臨床試驗、技術整合以及不斷成長的資金籌措表明，該市場前景光明。

全球基因治療市場按基因類型、治療方法類型、載體類型、遞送方法、給藥途徑、應用、最終用戶和地區進行細分。依基因類型分類，市場分為抗原、細胞激素、抑癌基因、自殺基因、缺陷基因、受體和其他基因。依治療方法類型分類，市場分為基因靜默療法、細胞替代療法、基因增強療法和其他治療方法。依載體類型分類，市場分為病毒載體和非病毒載體。依遞送方法分類，市場分為體外和體內遞送。

全球基因治療市場促進因素

全球基因治療領域正蓬勃發展，基因編輯技術的快速發展，尤其是CRISPR-Cas9等工具的出現，對其產生了顯著影響。這些創新技術提高了基因修飾的精準性、有效性和安全性，簡化了臨床開發流程，並為患者拓展了治療選擇。此外，載體療法的發展以及遞送機制的改進，也進一步推動了該領域的成長。隨著這些技術的不斷進步，它們正為治療格局帶來變革性的影響，使研究人員和醫療服務提供者能夠探索治療遺傳疾病的新途徑，並改善患者的治療效果。

限制全球基因治療市場的因素

全球基因治療市場成長面臨許多限制因素，包括長期安全性、脫靶效應和倫理挑戰。這些擔憂可能導致公眾和監管機構的質疑，從而延緩創新治療方法的推出。此外，由於相關人員需要解決圍繞基因工程的複雜問題，這種不確定性可能會抑制投資並阻礙整體市場發展。這些因素共同構成了基因治療發展和普及的重大挑戰，最終影響醫療保健領域創新治療方案的潛力。

全球基因治療市場趨勢

全球基因治療市場的一個顯著趨勢是，在基因組學和生物技術進步的推動下，精準醫療日益受到重視。這種轉變使得針對個體基因譜量身訂做標靶治療成為可能，從而提高了治療的有效性和安全性。此外，遺傳性疾病和慢性病的盛行率上升也推動了對基因治療的投資，因為相關人員認知到基因治療在滿足未被滿足的醫療需求方面的潛力。製藥公司與研究機構之間的合作也在增加，這促進了創新，加速了基因治療的商業化進程，從而擴大了基因治療的可及性，並改善了全球患者的治療效果。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Krystal Biotech（United States）
CRISPR Therapeutics（Switzerland）
Beam Therapeutics（United States）
Intellia Therapeutics（United States）
Korro Bio（United States）
Neurogene（United States）
Sangamo Therapeutics（United States）
MeiraGTx（United States）
Verve Therapeutics（United States）
Prime Medicine（United States）
Taysha Gene Therapies（United States）
enGene（Canada）
Voyager Therapeutics（United States）
Poseida Therapeutics（United States）
uniQure（Netherlands）
Editas Medicine（United States）
Benitec Biopharma（United States）
Cellectis SA（France）
Adverum Biotechnologies（United States）
Generation Bio（United States）

結論與建議

簡介目錄

Product Code: SQMIG35H2218

Global Gene Therapy Market size was valued at USD 9.00 Billion in 2024 and is poised to grow from USD 10.93 Billion in 2025 to USD 51.55 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The global gene therapy market is witnessing robust expansion driven by significant scientific advancements and the rising prevalence of genetic disorders. Increasing rates of rare and chronic conditions, such as hemophilia and cystic fibrosis, are catalyzing the development of targeted gene-based therapies. Innovations like CRISPR-Cas9 and adeno-associated virus vectors have improved the precision and safety of gene delivery methods. Regulatory endorsements of prominent therapies have spurred further investment and research. However, challenges remain, including high treatment costs that limit accessibility, complex production of viral vectors, safety concerns regarding immune responses, and regulatory hurdles, particularly in emerging markets. Despite these constraints, ongoing clinical trials and technological integrations, alongside increased funding, hint at a promising trajectory for the market's future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Therapy Market Segments Analysis

The global gene therapy market is segmented by Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user and region. Based on Gene Type, the market is segmented into Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Receptors and Others. Based on Therapy type, the market is segmented into Gene silencing therapy, Cell replacement therapy, Gene augmentation therapy and Other therapies. Based on Vector type, the market is segmented into Viral vector and Non-Viral Vector. Based on Delivery Method, the market is segmented into Ex-Vivo and In-Vivo.

Driver of the Global Gene Therapy Market

The expanding global gene therapy sector is significantly influenced by swift progress in gene editing techniques, particularly tools like CRISPR-Cas9. These innovative technologies enhance the precision, effectiveness, and safety of genetic modifications, thereby streamlining the clinical development process and broadening treatment options for patients. Furthermore, the development of vector-based methods coupled with improved delivery mechanisms is further driving growth in this field. As these advancements continue to evolve, they pave the way for a transformative impact on the therapeutic landscape, enabling researchers and healthcare providers to explore new possibilities in treating genetic disorders and enhancing patient outcomes.

Restraints in the Global Gene Therapy Market

The growth of the global gene therapy market faces various constraints, including concerns related to long-term safety, off-target effects, and ethical implications. These apprehensions may lead to skepticism among the public and regulatory bodies, potentially stalling the adoption of innovative therapies. Additionally, such uncertainties could deter investment and inhibit overall market development as stakeholders navigate the complexities surrounding genetic engineering. The combination of these factors can create significant challenges for the advancement and acceptance of gene therapies, ultimately impacting their potential to revolutionize treatment options in the healthcare sector.

Market Trends of the Global Gene Therapy Market

A significant trend in the global gene therapy market is the increasing focus on precision medicine, driven by advancements in genomics and biotechnology. This shift is enabling the development of targeted therapies that cater to individual genetic profiles, enhancing treatment efficacy and safety. Additionally, the rising prevalence of genetic disorders and chronic diseases is propelling investment in gene therapies, as stakeholders recognize their potential to address unmet medical needs. Collaborations between pharmaceutical companies and research institutions are also on the rise, facilitating innovation and accelerating the commercialization of gene therapies, thereby expanding access and improving patient outcomes globally.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Gene Therapy Market Size by Gene Type & CAGR (2026-2033)

Market Overview
Antigen
Cytokine
Tumor Suppressor
Suicide
Deficiency
Receptors
Others

Global Gene Therapy Market Size by Therapy type & CAGR (2026-2033)

Market Overview
Gene silencing therapy
Cell replacement therapy
Gene augmentation therapy
Other therapies

Global Gene Therapy Market Size by Vector type & CAGR (2026-2033)

Market Overview
Viral vector
- Retroviral vectors
- AAV Vectors
- Others
Non-Viral Vector
- Oligonucleotide Vectors
- Others

Global Gene Therapy Market Size by Delivery Method & CAGR (2026-2033)

Market Overview
Ex-Vivo
In-Vivo

Global Gene Therapy Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Intravenous Route
Subcutaneous Route
Others

Global Gene Therapy Market Size by Application & CAGR (2026-2033)

Market Overview
Oncological Disorders
Rare Diseases
Cardiovascular Diseases
Neurological Disorders
Infectious Disease
Other Diseases

Global Gene Therapy Market Size by End-user & CAGR (2026-2033)

Market Overview
Cancer Institutes
Hospitals
Research institutes
Others

Global Gene Therapy Market Size & CAGR (2026-2033)

North America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- US
- Canada
Europe (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- Brazil
- Rest of Latin America
Middle East & Africa (Gene Type, Therapy type, Vector type, Delivery Method, Route Of Administration, Application, End-user)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Krystal Biotech (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beam Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intellia Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Korro Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neurogene (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MeiraGTx (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Verve Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Prime Medicine (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taysha Gene Therapies (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
enGene (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Voyager Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Poseida Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Editas Medicine (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Benitec Biopharma (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cellectis S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Generation Bio (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments